This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Daiwa Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
In a report released on March 26, from Daiwa maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$42.00. The company’s shares closed last Wednesday at HK$31.54.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wuxi Biologics (Cayman) with a HK$45.08 average price target, which is a 42.92% upside from current levels. In a report released on March 26, CMB International Securities also maintained a Buy rating on the stock with a HK$39.00 price target.
The company has a one-year high of HK$44.00 and a one-year low of HK$16.20. Currently, Wuxi Biologics (Cayman) has an average volume of 35.15M.
Read More on WXIBF:
Disclaimer & DisclosureReport an Issue
- WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating
- Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme
- WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors
- Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands
- WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
